2025 Preliminary Earnings: Revenue and Operating Profit Up, Net Income Down Due to Additional Tax
-
Revenue: 774,800 million KRW (+7.7% YoY), Operating profit: 93,625 million KRW (+13.5%)
-
Net income: 61,689 million KRW (-5.2% YoY) due to additional corporate tax payments
-
Total assets: 604,878 million, Total liabilities: 234,959 million, Total equity: 369,918 million
-
Sales growth driven by focus on core products (Livalo, Livalozet)
-
Preliminary unaudited figures, subject to change after audit
KOSPI Filing Information
-
Filing: Change in Revenue or Profit Structure of Less Than 30% (15% for Large Corporations) (Voluntary Disclosure)
-
Company: JW Pharmaceutical (001060)
-
Submission: JW Pharmaceutical
-
Receipt: 02-02-2026
-
Under KRX KOSPI Market Division